Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chongyi Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0003-8713-7711; OpenAlex author ID A5103909044. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 7 papers · 2026: 1 paper

Papers 17

  1. SMAD4 Palmitoylation Drives a Metabolic-Transcriptional Circuit to Promote Tumorigenesis and Confers Radiosensitivity in Pancreatic Cancer. Co-author DOI 10.1002/advs.202519791↗
  2. CT-based machine learning radiomics predicts Ki-67 expression level and its relationship with overall survival in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-025-04798-y↗
  3. LINC00431 modulates KRAS and p53 stability to drive pancreatic cancer progression under hypoxia Last author DOI 10.1016/j.gendis.2025.101696↗
  4. A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy. Co-author DOI 10.1039/d4tb02206h↗
  5. Predictors for low rates of surgical resection in elderly patients with resectable pancreatic ductal adenocarcinoma: a retrospective case-control study. Last author DOI 10.1097/js9.0000000000001957↗
  6. An in-vivo pilot study of probe-based confocal laser endomicroscopy for detecting of pancreatic ductal adenocarcinoma intraoperatively. Last author DOI 10.1097/js9.0000000000003754↗
  7. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  8. CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis. Last author DOI 10.1186/s13046-025-03295-w↗
  9. Schwann cells in pancreatic cancer: Unraveling their multifaceted roles in tumorigenesis and neural interactions. Last author DOI 10.1016/j.canlet.2024.216689↗
  10. RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report. Last author DOI 10.3389/fonc.2023.1078076↗
  11. Adipocytes promote pancreatic cancer migration and invasion through fatty acid metabolic reprogramming. Last author DOI 10.3892/or.2023.8578↗
  12. PYGL-mediated glucose metabolism reprogramming promotes EMT phenotype and metastasis of pancreatic cancer. Co-author DOI 10.7150/ijbs.76756↗
  13. Low preoperative skeletal muscle index increases the risk of mortality among resectable pancreatic cancer patients: A retrospective study. Last author DOI 10.4240/wjgs.v14.i12.1350↗
  14. Cancer‑associated adipocytes exhibit distinct phenotypes and facilitate tumor progression in pancreatic cancer. Last author DOI 10.3892/or.2019.7365↗
  15. SNX6 predicts poor prognosis and contributes to the metastasis of pancreatic cancer cells via activating epithelial-mesenchymal transition. Co-author DOI 10.1093/abbs/gmy110↗
  16. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Co-author DOI 10.18632/oncotarget.14037↗
  17. Expression of the adipocytokine resistin and its association with the clinicopathological features and prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2012.865↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong‐Fei Yao · 7 shared papers, 2024–2025 · strength 1.75
  2. Zhiwei Cai · 8 shared papers, 2018–2025 · strength 1.60
  3. Chunjing Li · 6 shared papers, 2024–2025 · strength 1.47
  4. Jia-Hao Chen · 2 shared papers, 2025 · strength 0.53
  5. Tongyi Zhang · 2 shared papers, 2023–2025 · strength 0.47
  6. Zhen Cheng · 1 shared paper, 2025 · strength 0.28
  7. Guihua Zhou · 1 shared paper, 2025 · strength 0.28
  8. Xianjun Yu · 2 shared papers, 2018–2025 · strength 0.26
  9. Jianxia Ma · 1 shared paper, 2025 · strength 0.25
  10. Ming Li · 1 shared paper, 2025 · strength 0.25
  11. Feng Wang · 1 shared paper, 2026 · strength 0.24
  12. Yang Wang · 1 shared paper, 2026 · strength 0.24
  13. Yu-Heng Zhu · 1 shared paper, 2025 · strength 0.24
  14. Mingjian Ma · 1 shared paper, 2023 · strength 0.20
  15. Zhi-Wei Cai · 1 shared paper, 2022 · strength 0.20
  16. Bing Peng · 1 shared paper, 2025 · strength 0.19
  17. Xu Wang · 1 shared paper, 2025 · strength 0.19
  18. Jin Xu · 1 shared paper, 2025 · strength 0.19
  19. He Cheng · 1 shared paper, 2025 · strength 0.19
  20. Weiding Wu · 1 shared paper, 2025 · strength 0.19
  21. Wenyan Xu · 1 shared paper, 2025 · strength 0.19
  22. Wei Wang · 1 shared paper, 2025 · strength 0.19
  23. Chenghao Shao · 1 shared paper, 2025 · strength 0.19
  24. Chen Liu · 1 shared paper, 2025 · strength 0.19
  25. Rong Liu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.